Company: LIMN
Filing Date: 2025-01-15
Form Type: CORRESP
Source: 0001104659-25-003831
Chunk: 4

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-15
Form: CORRESP
Chunk 4
---
175,000,000 following the TDT License Termination. Please ensure your disclosure addresses how Iris Acquisition Corp negotiated the revised merger consideration in light of the loss of Liminatus’ clinical stage product candidate and that Liminatus is now a single-asset, pre-clinical company, and how the board determined the revised merger consideration was appropriate given those changes and determined that the transactions contemplated by the Business Combination Agreement were advisable and in the best interests of Iris and its stockholders.

:

In response to the Staff’s comment, the Company
has revised the disclosure on pages 113, 114, 116 and 117 of the Form S-4.

Business of Liminatus Pre-Clinical Development to Date, page 184

13. We note your pre-clinical development to date of the CD47 therapeutic candidate appears to have studied Hu3A5 in murine colon adenocarcinoma and that the anticipated clinical trials will focus on patients with lung cancer. Please disclose whether you will conduct additional pre-clinical studies that focus on lung cancer cells prior to the anticipated clinical trials.

:

In response to the Staff’s comment, the Company
has revised the disclosure on page 187 of the Form S-4.

CD47, page 190

14. We note your disclosure that Magrolimab, a CD47-targeting drug candidate, is in Phase 3 clinical trials and that this drug is expected to be the first CD47-targeted treatment to gain approval. If the study of this drug has been wound down by the developer, please update your disclosure as appropriate.

:

In response to the Staff’s comment, the Company
has revised the disclosure on pages 193 and 194 of the Form S-4.

The Company believes the foregoing
fairly responds to the Staff’s comment in its letter dated December 5, 2024, and is prepared to provide the Staff with additional
information. Thank you in advance for your assistance in this matter. If you have any questions or additional comments, please do not
hesitate to contact Chauncey Lane, at (214) 969-1278.

| Sincerely,    |                         |
| /s/ Chris Kim |                         |
| Name:         | Chris Kim               |
| Title:        | Chief Executive Officer |

cc: Chauncey Lane, Esq., Holland & Knight LLP